A new fluid biomarker for Parkinson’s disease (PD) was developed, offering a high-accuracy biological classification, ...

Despite the challenges associated with studying exosomes due to their low abundance, small size, and fragility, they are ...

Scientists see several important uses for staging. For example, it can steer people more precisely to appropriate treatments.

ARUP Laboratories has introduced a blood test for phosphorylated tau 217 (pTau 217) to aid in diagnosing the pathology of ...

In order to perform the CSF Oligoclonal Bands test, a sample of your cerebrospinal fluid is retrieved. The most common way to attain a sample is through a lumbar puncture, also known as a spinal ...

G-CSF has been evaluated as an adjunct to standard ... these findings are limited by factors such as small sample sizes, selection bias, and lack of an appropriate control group.

Researchers have identified a biomarker in spinal fluid that can detect Parkinson’s disease in its early stages with over 90% ...

A new blood test used to detect the pathology of Alzheimer’s Disease has just launched in Utah, and local experts are calling ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

These events are associated with innate training and can have long-term impacts on hematopoietic stem and progenitor cell (HSPC) development but can also compromise their function. While many ...

A new study confirms that plasma p-tau181 levels can identify subjective cognitive decline (SCD) as a distinct early stage of ...